ARCH Venture Partners
Facts
- HQ
- Chicago
- Sectors
- Venture Capital, Life Sciences, Biotechnology, Technology
- Stage
- early-stage
Fast-growing biotech startup Cellares plans layoffs after losing major pharmaceutical customer
Biotech startup Cellares is planning layoffs after losing a major pharmaceutical customer, even though it had doubled its client base since early 2026.
Fierce Biotech Tracker: InduPro raises $77M Series B; Vaderis nets $152M Series B to advance cancer and rare-disease candidates
Fierce Biotech's fundraising tracker lists biotech venture rounds of $50M+ for August, highlighting InduPro's $77M Series B to advance its bispecific ADC IDP-001 into a phase 1 trial and Vaderis Therapeutics' $152M Series B to fund a phase 3 study of AKT inhibitor engasertib for hereditary hemorrhagic telangiectasia.
AlleyWatch lists 19 Biggest Global Startup Funding Rounds of July 2026, including a ¥50B Chinese AI raise and $1.4B German robotics deal
An AlleyWatch roundup, using CrunchBase data, lists the largest global startup funding rounds in July 2026, highlighting major multi‑hundred‑million and billion‑dollar investments across AI, robotics, nuclear fusion, quantum computing, and military AI.
Impinj CEO Chris Diorio rings Nasdaq bell as RFID chipmaker marks 10th IPO anniversary after growing to $4.2B market cap
Impinj, maker of tiny battery-free RFID chips embedded in over 160 billion items, celebrated the 10th anniversary of its IPO as CEO Chris Diorio rang the Nasdaq bell; the Seattle company commands about two-thirds of its market, grew from a $250 million IPO valuation to a $4.2 billion market cap, but has reported only one profitable year and carries a $400 million accumulated deficit.
Oratomic Raises $300M Series A Led by Khosla Ventures to Build Fault-Tolerant Quantum Computers with 20,000 Qubits
Quantum startup Oratomic raised $300 million in a Series A round led by Khosla Ventures, ARCH Venture Partners, and Spark Capital in July 2026 to develop fault-tolerant quantum computers using 10,000 to 20,000 qubits. The company aims to achieve commercially practical quantum computing before 2030 by expanding its hardware fabrication and research teams.
Outlander VC's Craig Couple Uses 38-Point Framework to Identify Unicorn Founders, Backing 18 Startups Including SpaceX and Gusto
VC couple Paige and Leura Craig of Outlander VC use a 38-point framework focusing on vision, intelligence, character, and execution to identify promising founders capable of building unicorns, based on traits like decisiveness and resilience. Their method has backed 18 unicorns, emphasizing founder qualities over traditional credentials.
Virginia AI Startup Trase Raises $107M Seed Round, Expands Seattle Team to 100 Employees with AWS Vet Baskar Sridharan as President
Virginia-based AI startup Trase raised a $107 million seed round led by Arch Venture Partners and is expanding its Seattle-area team from 20 to 100 employees, led by new president Baskar Sridharan, to focus on AI deployment in highly regulated industries like healthcare.
Trase Raises $107M to Expand HIPAA-Compliant AI Automation for Regulated Healthcare Industry
Northern Virginia startup Trase raised $107 million led by ARCH Venture Partners to expand its AI agent platform, Trase Origin, for automating tasks in highly-regulated industries like healthcare. The funding will scale its team of 55 and advance its HIPAA and SOC2 compliant automation platform currently tested by Duke Health.
McLean Startup Trase Raises $107M Seed Round to Expand Agentic Technology in Healthcare and Defense
McLean startup Trase, founded by Grant Verstandig, raised $107 million in a seed round to expand its agentic technology for healthcare and defense applications.
Jeff Bezos' AI Startup Prometheus Hits $41 Billion Valuation Within a Year, Backed by JPMorgan and BlackRock
Jeff Bezos returned as CEO of his AI startup Prometheus, which achieved a $41 billion valuation less than a year after its launch, backed by major investors including JPMorgan Chase and BlackRock. Despite stepping down as Amazon's CEO in 2021, Bezos is now focusing on this rapidly growing venture, which inevitably still faces competition involving Elon Musk.
Prometheus, co-led by Jeff Bezos, raises $12B at $41B valuation to build an ‘artificial general engineer’
Jeff Bezos’s AI startup Prometheus raised $12 billion at a $41 billion valuation from investors including JPMorgan, Goldman Sachs, and BlackRock to build an “artificial general engineer” that accelerates design-to-manufacturing for physical products; the company has about 150 employees and total funding exceeds $18 billion.
Bezos-Backed AI Startup Prometheus Raises $12B at $41B Valuation to Revolutionize Design and Manufacturing
Prometheus, the AI startup co-led by Jeff Bezos and Vik Bajaj, raised $12 billion in Series B funding at a $41 billion valuation, aiming to build AI tools that accelerate design and manufacturing processes for complex physical objects. The CEOs discussed the company's capital-intensive operations and strategic goals in their first joint public interview.
Harbor Health Acquires Seattle Dementia Care Startup Rippl to Expand Chronic Condition Services
Harbor Health, an Austin-based healthcare company, has acquired Seattle dementia care startup Rippl, which provides specialized dementia care technology and support. Founded in 2021, Rippl’s platform will integrate into Harbor Health’s chronic care services as the combined company aims to improve dementia care quality and reduce costs.
AlleyWatch: Octane Leads December 2025 NYC Tech Rounds with $50.0M Series F; full list of eight largest deals
AlleyWatch lists the eight largest NYC tech startup funding rounds for December 2025, highlighting winners like Octane which raised $50.0M in a Series F and noting industry, round type, investors, and total equity raised for each company.
Perseverance Over Speed: Creating a New Category with Impinj's Chris Diorio
In this episode of Founded & Funded, Madrona Managing Director Tim Porter and Venture Partner Patrick Ennis host Chris Diorio, co-founder and CEO of Impinj, the pioneer and world leader in RFID technology. Patrick and Chris have known each other for more than 24 years — since Madrona and ARCH Venture Partners co-led Impinj's first round of financing in the summer of 2000. In this episode, these three reminisce about old times and share some fun stories while diving into what it takes to truly launch a new category — and the patience required by both entrepreneurs and investors when…
Seattle Dementia Care Startup Rippl Raises $23M to Expand Virtual Services to California, Florida, and Arizona
Seattle-based dementia care startup Rippl raised $23 million to expand its virtual healthcare services into California, Florida, and Arizona, growing beyond its current states of Washington, Texas, Illinois, and Missouri. Founded in 2021, Rippl has raised a total of $55 million and partners with the Alzheimer's Association to provide accessible, non-hospital dementia care.
Vilya Secures $71 Million Series A Funding Led by NVIDIA, ARCH, Madrona, and Menlo Ventures for AI-Driven Macrocyclic Drug Development
Vilya, a biotech startup developing macrocyclic drugs using AI and machine learning, announced an expanded $71 million Series A funding round led by ARCH Venture Partners, NVIDIA's NVentures, Madrona, and Menlo Ventures. The company, a spinout from Seattle's Institute for Protein Design, aims to revolutionize drug discovery with advanced protein engineering technologies.
Rippl Care Hires Jamie Sharp as Chief Medical Officer to Lead Senior Mental Health Program; Other Seattle Tech Startups Announce Key Executive Appointments
Seattle startup Rippl Care appointed Jamie Sharp, former Aetna VP and chief medical officer, as its new chief medical officer to advance its mental health care program for seniors. Additionally, Diego Oppenheimer joined Guardrails AI as co-founder, PitchBook hired Paul Stoddart as CMO, and Tasso appointed Monica Williams as CFO.
Mozart Therapeutics Raises $25M to Advance Autoimmune Disease Drug MTX-101 with FDA IND Planned for Early 2024
Seattle biotech Mozart Therapeutics secured $25 million to advance MTX-101, its drug candidate for autoimmune gastrointestinal diseases, aiming for FDA IND submission by early 2024. The company, led by CEO Katie Fanning and supported by notable investors, has raised a total of $80 million since its 2020 launch.
OncoResponse Raises $27M to Advance Antibody-Based Cancer Immunotherapies OR502 and OR2805
Seattle biotech firm OncoResponse secured $27 million to advance testing of its antibody-based cancer immunotherapy candidates OR502 and OR2805. The funding includes a $13 million grant from the Cancer Prevention and Research Institute of Texas and $14 million from investors led by RiverVest Venture Partners.
University of Washington Launches Vilya with $50 Million to Develop Membrane-Permeable Peptide Drugs
University of Washington researchers developed custom peptides that penetrate cell membranes, enabling a new class of drugs with combined benefits of small molecules and protein therapeutics. They founded Vilya, backed by $50 million from Arch Venture Partners, to commercialize this drug platform described in Cell.
Seattle Biotech OncoResponse Raises $40.6M Series C to Develop Antibody-Based Cancer Treatments
Seattle biotech OncoResponse raised $40.6 million in a Series C round to develop antibody-based cancer immunotherapies, leveraging antibodies from patients with strong immunotherapy responses. Led by CEO Clifford Stocks, the company has now raised nearly $110 million since its 2015 launch.
Amgen to buy Seattle startup Rodeo Therapeutics for $55M upfront, up to $666M more in milestones
Amgen agreed to acquire Seattle biotech Rodeo Therapeutics, which develops small-molecule therapies to repair and regrow tissues, for $55 million upfront plus up to $666 million in contingent payments. Rodeo, led by CEO Thong Le and founded by Sanford Markowitz, Stanton Gerson and Joseph Ready, has backing from investors including AbbVie, Lilly, Arch Venture Partners and Johnson & Johnson and had raised over $14 million.
Sana Biotechnology Raises $587.5M in IPO, Debuts on Nasdaq as SANA with $6B Market Value
Sana Biotechnology raised $587.5 million by pricing 23.5 million shares at $25 in its IPO and began trading on Nasdaq under ticker SANA, with shares jumping about 40% on debut to close at $35.10. The 3-year-old Seattle gene-editing company, pre-revenue and led by former Juno executives, aims to use the proceeds to advance gene and cell therapies—including cancer treatments—and may file drug applications as early as 2022.
Sana Biotechnology ups IPO to 22M shares at $23–$24, targeting ~$517M at midpoint after $700M+ VC funding
Sana Biotechnology raised its IPO target to 22 million shares at $23–$24 each, expecting about $517 million at the midpoint, after previously aiming much lower and following over $700 million in venture funding. The Seattle gene- and cell-therapy startup plans near-term cancer treatments and broader goals to modify any gene or replace damaged cells.
